3-(2-methoxy-5-methylphenyl)-3-phenylpropan-1-ol

We are 3-(2-methoxy-5-methylphenyl)-3-phenylpropan-1-ol CAS:124937-73-1 manufacturer and supplier in China, we can offer the best quality and price of 3-(2-methoxy-5-methylphenyl)-3-phenylpropan-1-ol, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests, thank you!

Chemical Name:  3-(2-methoxy-5-methylphenyl)-3-phenylpropan-1-ol
CAS.NO: 124937-73-1
Synonyms:
3-(2-methoxy-5-mehtylphenyl)-3-phenylpropanol
3-(2-methoxy-5-methyl-phenyl)-3-phenyl-propan-1-ol
3-(2-Methoxy-5-methylphenyl)-3-phenyl propanol

Molecular Formula:C17H20O2
Molecular Weight: 256.33900

Physical and Chemical Properties:
Density: 1.066 g/cm3
Boiling point: 413.8ºC at 760 mmHg
Melting point: /
Flash point: 184.2ºC
Refractive index: 1.561

Specification:
Appearance: White  powder
Purity:≥98%

Packing:
 25kg  cardboard drum or according to customer specified requirements
Storage:Stored in a cool and dry well-closed container. Keep away from moisture and strong light/heat.
Application:Intermediates of Tolterodine CAS:124937-51-5
Intermediates of Tolterodine tartrate CAS:124937-52-6

Related News: China has a complete upstream and downstream industry chain, lower costs, and good talent reserves. It is one of the few industries in China that has an advantage in international competition.5-nitro-2,3-dihydro-1-benzofuran China has a complete upstream and downstream industry chain, lower costs, and good talent reserves. It is one of the few industries in China that has an advantage in international competition.3-chloro-4-(pyridin-2-ylmethoxy)aniline CAS:524955-09-7 The term active pharmaceutical ingredient may refer to an active chemical within an FDA-regulated drug, or API might mean the entire drug with its active and inactive ingredients.2-isopropoxi-4,4,5,5-tetrametil-1,3,2-dioxaborolano CAS:61676-62-8 Oligomannate, which uses extract from marine brown algae as raw material, received a conditional green light to treat mild-to-moderate level AD, the National Medical Products Administration (NMPA) said in a statement on its website late on Saturday.In the context of increasingly tight global productive capacity cooperation in the pharmaceutical industry, some multinational pharmaceutical companies have chosen to abandon their original full industrial chain model and shift their focus to market operations. R & D, clinical, and production links reduce costs through outsourcing. Patented APIs came into being.